Article
Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication…
medRxiv · 2021 · Chaves, O. A.; Sacramento, C. Q.; Ferreira, A. C.; Mattos, M.; Fintelman-Rodrigues, N.; Temerozo, J. R.; Pinto, D. P.; da Silveira, G. P. E.; da Fonseca, L. B.; Pereira, H. M.; Carlos, A. S.; d'Avila, J. d. C. P.; Viola, J. P. B.; Monteiro, R. Q.; Vazquez, L.; Bozza, P. T.; Castro-Faria-Neto, H. C.; Souza, T. M. L.
Key facts
| Title | Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo |
|---|---|
| First author | Chaves, O. A.; Sacramento, C. Q.; Ferreira, A. C.; Mattos, M.; Fintelman-Rodrigues, N.; Temerozo, J. R.; Pinto, D. P.; da Silveira, G. P. E.; da Fonseca, L. B.; Pereira, H. M.; Carlos, A. S.; d'Avila, J. d. C. P.; Viola, J. P. B.; Monteiro, R. Q.; Vazquez, L.; Bozza, P. T.; Castro-Faria-Neto, H. C.; Souza, T. M. L. |
| Journal | medRxiv |
| Published | Nov 27, 2021 |
| DOI | 10.1101/2021.11.24.469775 |
| Devices mentioned | K090429 |
| Product codes mentioned | FMH, JJH, MQK |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1